Morning dosing may offer a slight edge here
K., Gurbuz, S., & Milicevic, Z
Tirzepatide occupies the middle ground Tirzepatide, a dual GIP/GLP-1 receptor agonist, showed a reporting odds ratio of 1.73, elevated but lower than semaglutide
We strongly encourage every GLP-1 patient to work with our Body and Wellness Program , led by: Amie Howard, CNS , our integrative nutritionist Desi Rotenburg, PA-C , our medical fitness clinician Together they provide daily macronutrient targets tailored to your body, protein goals that protect muscle while you lose fat, movement and strength programming, and sustainable habits you can carry forward long after the medication
True Value Score: B Lab Testing: What Gets Measured and Why It Matters Unlike many telehealth clinics, Eden does not routinely require lab work before prescribing GLP-1 medications